2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
You are currently not logged in to PHD
To view this content, please login to your account, or within the login, click 'Create an Account' for guest access.
Please note: American Heart Association does not associate with, nor endorse YouTube recommendations.
Steve Ommen, MD, FACC from the Mayo Clinic and Carolyn Ho, MD, FAHA from Brigham and Women's Hospital discuss the 2024 updates to the Hypertrophic Cardiomyopathy (HCM) Guidelines. They highlight the introduction of Mavacamten, the first cardiac myosin inhibitor, as a significant change following its FDA approval for symptomatic obstructive HCM.
Recommended Videos
Perioperative Algorithm from the 2024 Guideline for Perioperative Cardiova...
Myocardial Injury After Noncardiac Surgery
Key Updates from previous Guideline for Perioperative Cardiovascular Manag...
Key Concepts of Peripheral Vascular Interventions
Transformer Artery Approach vs Transradial Artery Approach in Peripheral V...
Loading...
Save Video
Please note: American Heart Association does not associate with, nor endorse YouTube recommendations.
Video is not available. Please check the URL.